Aarti Drugs Reports 6% Revenue Growth in Q1, Margins Improve Amid Input Cost Normalization 3 days ago
Aarti Drugs Limited reported a 6% year-on-year revenue growth to INR591.00 crores for the first quarter, with a 5% growth in API business volumes. EBITDA increased by 12% to INR74.00 crores, and net profit rose to INR54.00 crores from INR33.30 crores in the previous year's Q1. The company's gross profit margin improved by 130 basis points to 36.80%. Aarti Drugs has commenced trial production for anti-diabetic products at its Sayakha, Gujarat facility and expects its Tarapur salicylic acid facility to contribute from Q3. The formulation business grew by 14% to INR80.00 crores. The company received USFDA and UK MHRA approvals for its facilities and has positioned itself as a leading global metformin manufacturer.
Aarti Drugs Reports Strong Q1 FY26 Results, Expands Operations with New Facilities 10 days ago
Aarti Drugs Reports 6% Revenue Growth in Q1 FY26, Allocates Rs. 48.5 Crore for Capex 10 days ago
Aarti Drugs Reports Robust Q4 Performance with Significant Profit and Revenue Growth May 07, 2025
More news about Aarti Drugs
06May 25
Aarti Drugs Unveils Ambitious Production Expansion Strategy Through FY26
Aarti Drugs Limited has announced a strategic plan to significantly increase its production capacity. The company aims to boost production to over 700 tonnes per month by June 2025 and reach approximately 1,600 tonnes per month by the end of fiscal year 2026. This expansion is expected to enhance the company's market position and ability to meet growing demand in the pharmaceutical sector.
Aarti Drugs Limited announced impressive Q4 FY2023 financial results. Net profit rose 32.7% YoY to ₹62.86 crore, while revenue increased 9.2% to ₹677.00 crore. EBITDA grew 8.9% to ₹93.40 crore, with a stable EBITDA margin of 13.79%. The company showed significant quarter-on-quarter growth, with net profit jumping 69.7% from Q3 FY2023. These results highlight Aarti Drugs' strong market position, operational efficiency, and growth potential in the pharmaceutical sector.
07Mar 25
SEBI Issues Administrative Warning to Aarti Drugs for Insider Trading Regulation Violations
Aarti Drugs Limited has received an administrative warning letter from SEBI for alleged violations of insider trading regulations. The warning cites inadequate identification of immediate relatives of designated persons and non-application of the Code of Conduct on Prohibition of Insider Trading to certain immediate relatives. The company has committed to ensuring compliance and exercising caution to prevent recurrence. No financial impact or penalties have been imposed on the company.
06Mar 25
SEBI Issues Administrative Warning to Aarti Drugs' Compliance Officer Amid Insider Trading Concerns
SEBI has issued an administrative warning to Aarti Drugs Limited's Compliance Officer and Company Secretary for potential violations of insider trading regulations. The warning cites inadequate steps in identifying immediate relatives of Designated Persons and failure to apply the Code of Conduct on Prohibition of Insider Trading to certain relatives. Aarti Drugs has committed to ensuring compliance and exercising caution to prevent recurrence. The company states that this warning will not impact its financial, operational, or other activities.